Yale-linked Vera has rebranded from Trucode Gene Repair and will use the money to move towards clinical trials.
Vera Therapeutics, a US-based immunological and inflammatory disease therapy producer spun out of Yale University, has secured $80m of series C funding from investors including Alphabet’s early-stage corporate venturing unit GV.
The round was led by venture capital firm Abingworth and also attracted financial services group Fidelity Management & Research Company in addition to Alexandria Venture Investments, the strategic investment arm of life sciences real estate investment trust Alexandria Real Estate Equities.
Sofinnova Investments, Longitude Capital, asset management…
